Weekly pill could cut migraine days in half
NCT ID NCT07072910
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 36 times
Summary
This phase 2 trial tests whether a weekly dose of cabergoline, a drug that affects dopamine, can reduce the number of migraine days in adults with episodic migraine (4-14 migraine days per month). 150 participants will be randomly assigned to receive cabergoline (0.5 mg or 1.0 mg) or a placebo once a week for 12 weeks, followed by an open-label phase where everyone gets cabergoline. The study tracks migraine frequency, severity, and medication use through daily diaries and questionnaires.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aarhus University Hospital
RECRUITINGAarhus N, 8200, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cabergoline (Dostinex), a dopamine receptor agonist taken as a weekly oral tablet
What this could lead to
If it works, this could provide a new, once-weekly preventive option for people with episodic migraine, reducing the number of migraine days per month.
What could go wrong
This is an early phase 2 trial with only 150 participants, so results may not apply to everyone. Cabergoline can cause side effects like nausea, dizziness, or heart valve issues, and it may not prove more effective than placebo.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.